CSC: the industrial dividend of traditional Chinese medicine industry is not over, and the market will develop in depth

CSC research report pointed out that since 2021, the implementation speed of policies supporting the traditional Chinese medicine industry at the national level has significantly accelerated. The State Administration of traditional Chinese medicine has given directional guidance on the construction of industry capacity and system; The national medical insurance bureau and the administration of traditional Chinese medicine jointly issued the guiding opinions on medical insurance supporting the inheritance, innovation and development of traditional Chinese medicine, which requires deepening the reform of the medical security system and supporting and promoting the inheritance, innovation and development of traditional Chinese medicine; In terms of registration and approval, the state vigorously promotes the inheritance and innovation of traditional Chinese medicine. The number of innovative traditional Chinese medicine, whether applied for registration or approved, has reached a record high. In 2021, the approved new drug varieties are widely distributed in the field of disease treatment. However, at the same time, the centralized collection of traditional Chinese medicine by local alliances is also being promoted. The follow-up market of traditional Chinese medicine will develop in depth. Excellent companies that select traditional Chinese medicine consumer goods may be one of the important ideas.